Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$5.07 USD

5.07
230,350

+0.05 (1.00%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $5.05 -0.02 (-0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

by Zacks Equity Research

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why

by Zacks Equity Research

Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

by Zacks Equity Research

Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.

Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag

by Zacks Equity Research

Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

by Zacks Equity Research

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag

by Zacks Equity Research

AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Superlative Returns

by Tirthankar Chakraborty

Universal Technical Institute (UTI), Puma Biotechnology (PBYI), Nomura (NMR) and Navigator Holdings (NVGS) have been selected as the breakout stocks for today.

Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan

by Zacks Equity Research

Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.

SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why

by Zacks Equity Research

SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.

Amgen Inc. (AMGN) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

by Zacks Equity Research

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

PBYI or VRTX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. VRTX: Which Stock Is the Better Value Option?

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

by Zacks Equity Research

Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

by Zacks Equity Research

Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

by Zacks Equity Research

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

by Zacks Equity Research

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

by Zacks Equity Research

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

by Zacks Equity Research

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.

Should You Add Marinus (MRNS) Stock to Your Portfolio Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.